Blood Plasma Derivatives Market to reach US$ 51,119.24 million by 2028 | Grow CAGR of 9.4%

The global blood plasma derivatives market is witnessing robust growth, supported by the increasing prevalence of chronic and rare diseases, technological advancements in plasma fractionation, and expanding applications of plasma-derived therapies. According to The Insight Partners, the market is expected to reach US$ 51,119.24 million by 2028 from US$ 29,886.12 million in 2022, registering a compound annual growth rate (CAGR) of 9.4% from 2022 to 2028.

Download Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00007250?utm_source=OpenPR&utm_medium=10379

Blood plasma derivatives-therapeutic proteins isolated and purified from human plasma-play a vital role in saving millions of lives globally. These derivatives are widely used in the treatment of immune deficiencies, hemophilia, neurological disorders, burn care, and other critical conditions. The market's strong growth outlook reflects rising global demand for advanced biologics, improved diagnosis rates, and sustained investment in plasma collection and manufacturing infrastructure.

Market Overview

Blood plasma derivatives are categorized into albumin, immunoglobulins, coagulation factor concentrates, protease inhibitors, and other plasma-based products. Among these, immunoglobulins account for the largest market share due to their growing use in immunodeficiency diseases, autoimmune disorders, and neurological conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP).

The market spans North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America, with North America holding a dominant position due to its advanced healthcare infrastructure, high diagnosis rates, and strong presence of leading plasma fractionation companies.

Key Market Drivers

Rising Prevalence of Immune and Rare Disorders

One of the primary drivers of the blood plasma derivatives market is the increasing incidence of immune deficiencies and rare diseases worldwide. Disorders such as primary immunodeficiency (PID), hemophilia A and B, von Willebrand disease, and alpha-1 antitrypsin deficiency require long-term or lifelong plasma-derived therapies.

As awareness and diagnosis improve, demand for safe, effective, and high-quality plasma derivatives continues to grow. This trend is particularly evident in developed economies, where early diagnostics and access to specialty treatments are becoming standard.

Growing Demand for Immunoglobulins

Immunoglobulins represent the most rapidly expanding product segment within the blood plasma derivatives market. Their use has expanded beyond traditional immune deficiencies to include neurology, hematology, and transplant medicine.

The rising prevalence of autoimmune and neurological disorders, coupled with off-label use in emergency and critical care settings, has significantly accelerated global immunoglobulin consumption. This sustained demand is a major contributor to the market's strong CAGR through 2028.

Aging Population and Chronic Disease Burden

The global population is aging rapidly, leading to higher incidences of chronic diseases that require plasma-derived therapies. Older adults are more vulnerable to immune deficiencies, neurological disorders, and coagulation abnormalities.

As healthcare systems adapt to the needs of aging demographics, plasma derivatives are increasingly being integrated into long-term disease management protocols, boosting overall market revenues.

Advances in Plasma Fractionation Technologies

Technological innovations in plasma collection, fractionation, purification, and pathogen inactivation have significantly improved product yield, safety, and consistency. Modern fractionation techniques allow manufacturers to extract multiple high-value proteins from a single plasma unit, enhancing operational efficiency.

Additionally, advancements in cold ethanol fractionation, chromatography, and viral inactivation processes have increased regulatory confidence, supporting broader clinical adoption.

Expansion of Plasma Collection Infrastructure

To meet rising global demand, market players are intensifying investments in plasma donation centers and supply chain optimization. The expansion of plasma collection networks, particularly in North America and parts of Europe, is helping ensure reliable raw material availability.

Emerging economies in Asia Pacific are also witnessing increased investment in plasma-derived product manufacturing, driven by growing healthcare expenditure and supportive government initiatives.

Explore Full Report Data @ https://www.theinsightpartners.com/reports/blood-plasma-derivatives-market

Increasing Applications in Critical Care and Emergency Medicine

Plasma derivatives such as albumin are widely used in trauma care, burn treatment, liver disease management, and shock therapy. Growth in emergency medicine services and critical care units worldwide is further accelerating demand for plasma-derived solutions.

The ongoing need for rapid, effective therapies in intensive care settings positions blood plasma derivatives as essential components of modern healthcare systems.

Market Challenges and Opportunities

While the market outlook remains strong, challenges such as high production costs, lengthy regulatory approval processes, and plasma supply constraints persist. However, these challenges are being counterbalanced by opportunities including:

Increasing approval of new plasma-derived indications
Strategic partnerships and mergers among leading players
Expansion into untapped emerging markets
Growing focus on recombinant-plasma hybrid therapies
With continuous R&D investment and supportive regulatory frameworks, the market is well-positioned to overcome hurdles and sustain long-term growth.

Regional Insights

North America

North America dominates the blood plasma derivatives market due to its high number of plasma donation centers, advanced healthcare infrastructure, and strong reimbursement systems. The United States, in particular, leads global plasma collection and fractionation capacity.

Europe

Europe represents a mature market with well-established regulatory standards and growing demand for immunoglobulins. Countries such as Germany, France, and the UK are witnessing steady adoption of plasma-derived therapies across multiple clinical areas.

Asia Pacific

Asia Pacific is expected to record the fastest growth rate during the forecast period, driven by rising healthcare investments, increasing disease prevalence, and improving awareness of plasma-derived treatments. Expansion of domestic manufacturing capacities in countries like China and India is further supporting regional growth.

Competitive Landscape

Get Full Copy @ https://www.theinsightpartners.com/buy/TIPRE00007250?utm_source=OpenPR&utm_medium=10379

The global blood plasma derivatives market is moderately consolidated, with key players focusing on capacity expansions, product innovation, and strategic collaborations. Major companies operating in the market include:
CSL Behring
Grifols, S.A.
Takeda Pharmaceutical Company Limited
Octapharma AG
Kedrion Biopharma
Biotest AG
LFB Group
Bio Products Laboratory (BPL)
SK Plasma

These companies are actively investing in new plasma collection centers, adopting advanced fractionation technologies, and strengthening global distribution networks to gain a competitive edge.

Market Outlook Through 2028

With strong fundamentals and expanding therapeutic applications, the blood plasma derivatives market is on a path of sustained growth. The market's anticipated rise to US$ 51,119.24 million by 2028, at a CAGR of 9.4%, reflects increasing reliance on plasma-derived products for chronic and acute disease management.

Continuous innovation, expanding donor networks, and supportive healthcare policies will remain critical success factors shaping the market's future.

Related Reports @

Bovine Blood Plasma Derivatives Market @ https://www.theinsightpartners.com/reports/bovine-blood-plasma-derivatives-market

About Us -
The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

This release was published on openPR.